Development of a multiphase patient-reported outcomes dashboard to support population health and drive quality improvement in ambulatory oncology.

person Sunyi Zhang Dana-Farber Cancer Institute, Boston, MA info_outline Sunyi Zhang, Michael Manni, Sarah Whittaker, Paige Barwick, Brian Finn, Mary Schindler, Gabe Verzino, Niren Sirohi, Jason Johnson, Ellana K Haakenstad, Hakim Lakhani, Michael J. Hassett, Nadine Jackson McCleary

Authors person Sunyi Zhang Dana-Farber Cancer Institute, Boston, MA info_outline Sunyi Zhang, Michael Manni, Sarah Whittaker, Paige Barwick, Brian Finn, Mary Schindler, Gabe Verzino, Niren Sirohi, Jason Johnson, Ellana K Haakenstad, Hakim Lakhani, Michael J. Hassett, Nadine Jackson McCleary Organizations Dana-Farber Cancer Institute, Boston, MA, Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA Abstract Disclosures Research Funding No funding received None. Background: The Patient Reported Data (PRD) Program at Dana-Farber Cancer Institute (DFCI) has implemented a portfolio of electronic questionnaires including patient-reported outcome measures (PROMs) and risk screeners in routine practice. Over 141,906 questionnaires have been completed by over 60,158 patients across solid tumor, liquid tumor, and supportive care (see table). We are now prepared to share this data internally in an accessible and actionable format via the development of an Outcomes Dashboard. Methods: PRD and the DFCI Clinical Operations & Business Analytics team created a roadmap for iterative dashboards to be developed with Tableau 2022.1, a business analytics platform. The development team included a business analyst, data scientist, and content experts. The goal of our roadmap was to balance rapid delivery of data with the resources needed to develop more complex dashboards incorporating PRD with other data. The Outcomes Dashboard roadmap consists of four phases. Phase 1 focuses on creating a core dashboard and displaying aggregate PROMs-derived scores and risk scores with filters and stratification by patient demographics and clinical encounter data. Phase 2 adds clinical outcomes data including hospitalizations and treatment adherence. Phase 3 adds non-scored questionnaire data such as social determinants of health. Phase 4 incorporates oncology treatment data including treatment route, goals, class, and other characteristics. Results: Data was generated using Microsoft SQL Server Management Studio and loaded into Tableau to create visualizations with data refreshed daily. Dashboard Phase 1 is complete and will be released in spring 2023. Dashboard users will include executive leaders, operations, clinicians, and others. The dashboard will be used to identify differences and disparities in care delivery and outcomes by disease type, treatment, and other characteristics; highlight opportunities for interventions to improve quality and care delivery; identify areas for future research; and help fulfill emerging regulatory requirements. Conclusions: By making aggregate PRD and associated outcomes available in an accessible format, we aim to drive quality improvement and enable population health management. Future efforts will include educating users, assessing uptake of the dashboard, and partnering with stakeholders to develop clinical interventions to improve outcomes. Unique responses by care type*. Type All Solid Tumor Liquid Tumor Supportive Symptoms (PRO-CTCAE) 90,192 65,098 18,753 6,341 Global Health (PROMIS-10) 37,125 35,435 1,621 69 Head & Neck Quality of Life (EORTC HN43) 6,617 6,617 0 0 Oral Health Quality of Life (OHIP-14) 1,144 0 0 1,144 Anxiety (GAD-7) 1,354 0 0 1,354 Depression (PHQ-9) 1,321 0 0 1,321 Risk Screening 4,153 2,854 0 1,299 Total 141,906 110,004 20,374 11,528 *Data as of 1/31/23.